Skip to search.
 STI Up0.39%

Endo Health Solutions Inc. (ENDP)

-NasdaqGS

34.04 Up 0.31(0.92%) 04:00 SGT|After Hours : 33.96 Down 0.08 (0.22%) 04:10 SGT

Add to Portfolio
ProfileGet Profile for:
Endo Health Solutions Inc.
1400 Atwater Drive
Malvern, PA 19355
United States - Map
Phone: 484-216-0000
Fax: 800-329-3636
Website: http://www.endo.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:4,629

Business Summary 

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel for pain, urology, endocrinology, and oncology. Its Qualitest segment provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets. The company’s AMS segment offers various technology solutions comprising AMS 700 MS series, AMS 800 artificial urinary sphincter, GreenLight XPS laser system, Elevate transvaginal pelvic floor repair system, and Monarc subfascial hammock products in the areas of men’s and women’s health, and BPH therapy. Its HealthTronics segment provides urological services, such as lithotripsy, prostate treatment, anatomical pathology, and electronic medical record services to urologists, hospitals, surgery centers, and clinics; and manufactures, sells, and maintains medical devices for tissue and tumor ablation. The company’s products under development primarily include Aveed, an injectable testosterone preparation to treat male hypogonadism; BEMA Buprenorphine, a transmucosal form of buprenorphine in Phase III trials for treating moderate to severe chronic pain; ODM-201, an androgen receptor antagonist in Phase II clinical testing to treat castrate resistant prostate cancer; and EN3342, a polyurethane implant in Phase I/II trials for the maintenance treatment of schizophrenia in adults. It serves pharmacy chains directly; and hospitals, governmental agencies, pharmacies, and physicians through wholesale drug distributors. The company was formerly known as Endo Pharmaceuticals Holdings Inc. and changed its name to Endo Health Solutions Inc. in May 2012. Endo Health Solutions Inc. was founded in 1997 and is headquartered in Malvern, Pennsylvania.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Endo Health Solutions Inc.

Key Executives 
 PayExercised
Mr. Alan G. Levin CPA, 50
Chief Financial Officer and Exec. VP
744.00K70.00K
Ms. Julie H. McHugh , 49
Chief Operating Officer
679.00K0.00
Dr. Ivan P. Gergel M.D., 52
Chief Scientific Officer and Exec. VP of R&D
746.00K0.00
Mr. Caroline B. Manogue Esq., 43
Exec. VP, Chief Legal Officer and Sec.
651.00K0.00
Mr. Rajiv De Silva , 46
Chief Exec. Officer, Pres and Director
N/AN/A
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders